Gavi finalizes agreements with Sinopharm and Sinovac for COVAX supply
Deal makes doses of Covid-19 vaccine available to help address immediate and critical gaps in supply
Gavi, the Vaccine Alliance has signed advance purchase agreements (APAs) with Sinopharm for its “BBIBP-CorV” inactivated virus vaccine against Covid-19, along with Sinovac for its inactivated virus vaccine against Covid, known as “CoronaVac”. The deals will make 110 million doses immediately available to participants of the COVAX Facility—whose goal is to deliver vaccines to the world’s most vulnerable individuals—with the option for more doses.
Under the Sinopharm APA, Gavi will purchase 60 million doses that will be made available from July through October 2021 for Q3 supply. In addition, Gavi has the option to purchase another 60 million doses in Q4 and 50 million more doses in the first half of 2022, if needed. This equals a possible 170 million doses of the Sinopharm vaccine that could be made available to self-financing facility participants, as well as participants supported by the Gavi COVAX Advance Market Commitment (AMC).
Similar to Sinopharma, Sinovac’s APA also enables Q3 supply, and Gavi will be buying 50 million doses to be made available from July through September 2021. In addition, Gavi has the option to purchase a further 150 million doses in Q4 2021 and 180 million more doses in the first half of 2022. In total, up to 380 million potential doses of the Sinovac vaccine could be available to the same parties.
